Deakin University
Browse
skvarc-effectofadjunctive-2021.pdf (164 kB)

The Effect of Adjunctive Mangosteen Pericarp on Cognition in People With Schizophrenia: Secondary Analysis of a Randomized Controlled Trial

Download (164 kB)
journal contribution
posted on 2021-06-01, 00:00 authored by Wolf Marx, David SkvarcDavid Skvarc, Mohammadreza MohebbiMohammadreza Mohebbi, Adam WalkerAdam Walker, Alcy Meehan, Alyna TurnerAlyna Turner, Andrea Baker, Seetal DoddSeetal Dodd, Sue M Cotton, James Graham Scott, Bianca KavanaghBianca Kavanagh, Melanie AshtonMelanie Ashton, Ellie Brown, John J McGrath, Michael BerkMichael Berk, Olivia DeanOlivia Dean
Background: Cognitive impairment is prevalent and often highly burdensome in people with schizophrenia. The aim of this study was to investigate if mangosteen (Garcinia mangostana Linn.) pericarp extract may be an effective intervention to improve cognitive performance in this population.Methods: This was a secondary analysis of a larger randomized placebo-controlled trial that investigated a 24-weeks intervention of mangosteen pericarp extract supplementation in people diagnosed with schizophrenia. A subset of n = 114 participants with completed cognitive outcomes at follow up were included in this analysis. Using the Cogstate Brief Battery, the following cognitive outcomes were assessed: psychomotor function, attention, visual learning and memory (visual and working). Subgroup analyses investigated whether baseline clinical parameters (baseline cognitive functioning, illness severity and duration, depressive symptoms) moderated the relationship between mangosteen pericarp extract intervention and change in cognitive outcomes.Results: There were no significant between-group changes in any cognitive outcomes assessed. Subgroup analysis based on baseline cognition and clinical characteristics did not reveal any significant between-group difference in change.Conclusions: Mangosteen pericarp extract did not affect cognitive outcomes in people with schizophrenia. Further investigation regarding optimal dosing strategies for mangosteen interventions and the testing of additional cognitive domains may be warranted.Trial Registration:ANZCTR.org.au identifier: ACTRN12616000859482, registered 30 June 3 2016.

History

Journal

Frontiers in Psychiatry

Volume

12

Article number

626486

Pagination

1 - 8

Publisher

Frontiers Media

Location

Lausanne, Switzerland

ISSN

1664-0640

eISSN

1664-0640

Language

English

Publication classification

C1 Refereed article in a scholarly journal

Usage metrics

    Research Publications

    Categories

    No categories selected

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC